Findings from an accepted manuscript published in the American Journal of Roentgenology (AJR) suggest that for patients with dense breasts undergoing screening in the incidence setting, a commercial AI tool did not provide additional benefit to mammography with supplementary ultrasound (US).

57-YO woman with dense breasts—screening mammography (not shown) assessed BI-RADS 2. a. Supplementary screening breast ultrasound performed on same day as mammogram shows 4-mm round hypoechoic mass with angular margins in right upper medial breast. b. Screenshot of output of AI tool. Tool assigned abnormality score of “low” in each breast. Ultrasound-guided core biopsy and surgery revealed invasive ductal carcinoma, not otherwise specified (Luminal A, histologic grade I). Case represents false-negative AI result. 


July 28, 2023 — Findings from an accepted manuscript published in the American Journal of Roentgenology (AJR) suggest that for patients with dense breasts undergoing screening in the incidence setting, a commercial AI tool did not provide additional benefit to mammography with supplementary ultrasound (US). 

“Mammography with supplementary ultrasound showed higher accuracy, higher specificity, and lower recall rate in comparison to mammography with AI, as well as in comparison to mammography with both US and AI,” wrote corresponding author Hee Jung Moon, MD, PhD, from the department of radiology at South Korea’s Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine. 

This AJR accepted manuscript included 1,325 women (mean age, 53 years) with dense breasts who underwent both screening mammography and supplementary breast US within a 1-month interval from January 2017 to December 2017; prior mammogram and US were available to compare in 91.2% and 91.8%, respectively. Fifteen radiologists (5 staff and 10 fellows) interpreted mammography and US examinations, and clinical reports were used for Moon et al.’s analysis. A commercially available AI algorithm (Lunit INSIGHT, v 1.1.0.0, Seoul, Korea) was used to retrospectively evaluate mammographic examinations for cancer presence. Then, screening performances were compared among mammography, AI, US, and test combinations, using generalized estimating equations. At least 24 months of imaging stability was required for a benign diagnosis. 

Ultimately, mammography with AI, mammography with US, and mammography with both ultrasound and AI showed recall rate of 14.9, 11.7, and 21.4 (all p < .05); sensitivity of 83.3%, 100.0%, and 100.0% (all p > .05); specificity of 85.8%, 89.1%, and 79.4% (all p < .05); and accuracy of 85.7%, 89.2%, and 79.5% (all p < .05). 

For more information: www.arrs.org 


Related Content

News | Information Technology

April 25, 2024 — NewVue Inc., a leader in innovative cloud-native radiology workflow solutions, announced a strategic ...

Time April 25, 2024
arrow
News | Ultrasound Imaging

April 22, 2024 — GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which ...

Time April 22, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Radiology Business

April 17, 2024 — VISTA.AI announced the appointment of Daniel Hawkins as President and CEO. The company is pioneering AI ...

Time April 17, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time April 15, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
Subscribe Now